MD Anderson announces plan to eliminate cervical cancer in Texas
Texas has an incidence rate of 9.5 cervical cancer cases per 100,000 women, surpassing the national average of 7.5 per 100,000. Responding to these disparities, The University of Texas MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032 during the Cancer Prevention and Research Institute of Texas (CPRIT) 2026 Innovations Conference.
- The five-year roadmap aims to reduce cervical cancer incidence below four new cases per 100,000 women annually across Texas by 2032.
- The initiative rests on three specific pillars: increasing HPV vaccination to 80% for children up to age 15, raising screening adherence to 80% among women, and securing prompt diagnostic follow-ups and treatment for 80% of patients.
- Strategies incorporate advanced self-collection options for human papillomavirus testing and targeted patient support within uninsured, rural, and border communities.
The Texas Lone Star Cervical Cancer Elimination Plan 2027-2032 Unveiled at CPRIT Conference
Developed through the Cancer Alliance of Texas Cervical Cancer Elimination Priority Area Workgroup, the newly unveiled roadmap responds to a statewide survey and virtual summits involving more than 250 participants. The collaborative framework aligns directly with priorities set forth in the 2024 Texas Cancer Plan. More than 40 coalition members signed a joint declaration supporting the initiative.
“Texas has the tools to prevent nearly every case of cervical cancer, but tools can save lives only when people can utilize them,” Ernest Hawk, M.D., vice president and division head of Cancer Prevention and Population Sciences at UT MD Anderson, stated in the announcement. Hawk emphasized that expanded utilization of HPV self-collection and coordinated regional partnerships bring disease elimination within reach.
The strategic blueprint addresses severe geographic and demographic disparities within the state. While the overall state incidence sits at 9.5 per 100,000, certain Texas counties record incidence rates scaling between 15 and 21 per 100,000. These burdens fall disproportionately on minority, rural, border, and uninsured populations. Correspondingly, UT MD Anderson previously secured a $1.4 million grant from the Cancer Prevention and Research Institute of Texas to bolster screening and preventative treatments in the Rio Grande Valley, where cervical cancer death rates exceed the rest of the state by 30%, according to institutional findings.
Framework Sets 2032 Targets for Vaccination, Screening and Treatment
The framework establishes quantifiable metrics across three core operational pillars to be achieved by 2032:
| Strategic Pillar | Baseline Metric | 2032 Target Goal |
|---|---|---|
| HPV Vaccination | 50.5% of boys and girls up to date by age 15 | 80% coverage |
| Cervical Cancer Screening | 64% of women up to date | 80% participation (incorporating primary HPV testing and self-collection) |
| Diagnostic Follow-up and Treatment | Variable baseline access in underserved regions | 80% completion rate for necessary diagnostic care and treatment |
Patient support serves as an integral cross-cutting mechanism across all three operational areas. Sharyn Malatok, chair of the Cancer Alliance of Texas, emphasized the human element behind the epidemiological data. “Behind every cervical cancer statistic is a woman who didn’t get a screening, a family that didn’t have a trusted person to guide them or a community that was overlooked,” Malatok noted, highlighting that intervention relies heavily on community health workers and promotores meeting populations directly within local clinics, schools, and churches.
Global Collaborations and Technological Innovations in Prevention
To support resource-limited settings both within Texas and internationally, researchers continue to refine low-cost diagnostic technologies. UT MD Anderson has partnered with Rice University to develop novel screening instruments, including the high-resolution microendoscope designed to detect pre-cancerous lesions where advanced healthcare infrastructure is absent. These engineering solutions complement clinical efforts by expanding the capacity of healthcare practitioners to manage abnormal Pap test results effectively.
Achieving the 2032 elimination threshold—defined scientifically as fewer than four new cases per 100,000 women per year—requires systematic alignment among policymakers, healthcare systems, schools, and local funders. Individuals seeking guidance on screening schedules or preventative clinical resources can consult qualified primary care physicians, gynecologists, or specialized oncology navigators to ensure timely evaluation.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.